用纳米配方的小干扰RNA攻克乳腺癌化疗耐药性
Tackling breast cancer chemoresistance with nano-formulated siRNA.
作者信息
Jones S K, Merkel O M
机构信息
Department of Oncology, Wayne State University, Detroit, MI, USA.
Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI, USA.
出版信息
Gene Ther. 2016 Dec;23(12):821-828. doi: 10.1038/gt.2016.67. Epub 2016 Sep 20.
Abstract
Breast cancer is the leading cancer diagnosed in women and the second leading cause of cancer-related deaths in women. Current limitations to standard chemotherapy in the clinic are extensively researched, including problems arising from repeated treatments with the same drugs. The phenomenon that cancer cells become resistant toward certain chemo drugs is called chemotherapy resistance. In this review, we are focusing on nanoformulation of siRNA for the fight against breast cancer chemoresistance.
摘要
乳腺癌是女性中诊断出的最常见癌症，也是女性癌症相关死亡的第二大主要原因。目前临床上标准化疗的局限性已得到广泛研究，包括使用相同药物反复治疗所产生的问题。癌细胞对某些化疗药物产生耐药性的现象称为化疗耐药性。在本综述中，我们重点关注用于对抗乳腺癌化疗耐药性的siRNA纳米制剂。
相似文献
1
Tackling breast cancer chemoresistance with nano-formulated siRNA.用纳米配方的小干扰RNA攻克乳腺癌化疗耐药性
Gene Ther. 2016 Dec;23(12):821-828. doi: 10.1038/gt.2016.67. Epub 2016 Sep 20.
2
Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?纳米颗粒-siRNA：卵巢癌治疗的潜在策略？
Nanomedicine (Lond). 2019 Aug;14(15):2083-2100. doi: 10.2217/nnm-2018-0379. Epub 2019 Aug 1.
3
Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.小干扰RNA预暴露对后续小干扰RNA治疗反应的影响。
Pharm Res. 2015 Dec;32(12):3813-26. doi: 10.1007/s11095-015-1741-z. Epub 2015 Jul 1.
4
Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.TWIST小干扰RNA和抗癌药物的纳米颗粒递送：一种抗癌治疗方法
Enzymes. 2018;44:83-101. doi: 10.1016/bs.enz.2018.08.004. Epub 2018 Oct 5.
5
Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.通过多功能化纳米颗粒系统递送至肿瘤相关巨噬细胞和乳腺癌细胞，实现 VEGF 和 PIGF siRNA 的联合抗肿瘤免疫治疗。
Biomaterials. 2018 Dec;185:117-132. doi: 10.1016/j.biomaterials.2018.09.017. Epub 2018 Sep 11.
6
Effects of targeted nano-delivery systems combined with hTERT-siRNA and Bmi-1-siRNA on MCF-7 cells.靶向纳米递送系统联合hTERT-siRNA和Bmi-1-siRNA对MCF-7细胞的影响。
Int J Clin Exp Pathol. 2015 Jun 1;8(6):6674-82. eCollection 2015.
7
Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.还原/光双重响应型聚合物前药纳米粒用于程序性 siRNA 和阿霉素的递送。
Biomater Sci. 2018 May 29;6(6):1457-1468. doi: 10.1039/c8bm00226f.
8
Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.癌症小鼠模型中体内小干扰RNA递送的评估
Methods Mol Biol. 2016;1402:189-197. doi: 10.1007/978-1-4939-3378-5_15.
9
Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.仿生药物递送材料：探索肺表面活性剂在 siRNA 吸入治疗中的作用。
J Control Release. 2015 Dec 28;220(Pt B):642-50. doi: 10.1016/j.jconrel.2015.09.004. Epub 2015 Sep 10.
10
Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.纳米颗粒介导的小干扰RNA递送用于有效的肺癌治疗。
Nanomedicine (Lond). 2015;10(7):1165-88. doi: 10.2217/nnm.14.214.
引用本文的文献
1
Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer.siRNA 的治疗递送在乳腺癌和三阴性乳腺癌治疗中的应用。
Ther Deliv. 2024;15(11):871-891. doi: 10.1080/20415990.2024.2400044. Epub 2024 Sep 25.
2
HDL-Chitosan Nanoparticles for siRNA Delivery as an SR-B1 Receptor Targeted System.载 siRNA 的高密度脂蛋白-壳聚糖纳米粒作为一种 SR-B1 受体靶向系统。
Comb Chem High Throughput Screen. 2023;26(14):2541-2553. doi: 10.2174/1386207326666230406124524.
3
Octreotide-Targeted Lcn2 siRNA PEGylated Liposomes as a Treatment for Metastatic Breast Cancer.奥曲肽靶向的Lcn2小干扰RNA聚乙二醇化脂质体用于转移性乳腺癌的治疗
Bioengineering (Basel). 2021 Apr 3;8(4):44. doi: 10.3390/bioengineering8040044.
4
In-Vitro Application of Magnetic Hybrid Niosomes: Targeted siRNA-Delivery for Enhanced Breast Cancer Therapy.磁性混合脂质体的体外应用：用于增强乳腺癌治疗的靶向性小干扰RNA递送
Pharmaceutics. 2021 Mar 16;13(3):394. doi: 10.3390/pharmaceutics13030394.
5
Insight Into the Prospects for RNAi Therapy of Cancer.癌症RNA干扰疗法的前景洞察
Front Pharmacol. 2021 Mar 16;12:644718. doi: 10.3389/fphar.2021.644718. eCollection 2021.
6
Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems.乳腺癌化疗耐药机制及药物递送系统中的潜在靶点
Pharmaceutics. 2020 Dec 9;12(12):1193. doi: 10.3390/pharmaceutics12121193.
7
NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.NT21MP 通过靶向 CXCR4 通路中的 miR-155-3p 和 miR-155-5p 负调控乳腺癌紫杉醇耐药细胞。
Int J Oncol. 2018 Sep;53(3):1043-1054. doi: 10.3892/ijo.2018.4477. Epub 2018 Jul 9.
8
Correlating quantitative tumor accumulation and gene knockdown using SPECT/CT and bioluminescence imaging within an orthotopic ovarian cancer model.在卵巢癌原位模型中，使用 SPECT/CT 和生物发光成像定量肿瘤积累与基因敲低的相关性。
Biomaterials. 2018 Sep;178:183-192. doi: 10.1016/j.biomaterials.2018.06.014. Epub 2018 Jun 13.
9
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.非编码 RNA 在心血管疾病中的作用：诊断与治疗前景。
Eur Heart J. 2018 Aug 1;39(29):2704-2716. doi: 10.1093/eurheartj/ehx165.
本文引用的文献
1
Recent progress in development of siRNA delivery vehicles for cancer therapy.近年来用于癌症治疗的 siRNA 递药载体的研究进展。
Adv Drug Deliv Rev. 2016 Sep 1;104:61-77. doi: 10.1016/j.addr.2016.06.011. Epub 2016 Jun 25.
2
Calcium phosphate nanoparticles-based systems for siRNA delivery.基于磷酸钙纳米颗粒的 siRNA 递送系统。
Regen Biomater. 2016 Sep;3(3):187-95. doi: 10.1093/rb/rbw010. Epub 2016 Mar 4.
3
The fate of chemoresistance in triple negative breast cancer (TNBC).三阴性乳腺癌（TNBC）中化疗耐药的命运。
BBA Clin. 2015 Mar 12;3:257-75. doi: 10.1016/j.bbacli.2015.03.003. eCollection 2015 Jun.
4
Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.通过叶酸修饰的核壳纳米胶束共递送P-糖蛋白小干扰RNA和阿霉素逆转多药耐药性乳腺癌
Colloids Surf B Biointerfaces. 2016 Feb 1;138:60-9. doi: 10.1016/j.colsurfb.2015.11.041. Epub 2015 Nov 25.
5
Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β-tubulin in drug-resistant breast cancers.载硒纳米粒与混合 siRNA 共递送系统克服 P-糖蛋白和 III 类 β-微管蛋白介导的耐药性在耐药性乳腺癌中的应用。
Acta Biomater. 2016 Feb;31:197-210. doi: 10.1016/j.actbio.2015.11.041. Epub 2015 Nov 27.
6
Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.携载靶向毒性双功能谷氨酸-氨甲蝶呤连接物的 EG5siRNA 纳米复合物的双重抗肿瘤效力。
Biomaterials. 2016 Jan;77:98-110. doi: 10.1016/j.biomaterials.2015.11.004. Epub 2015 Nov 5.
7
Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes.通过包裹小干扰RNA（siRNA）和百里醌的多层金质非离子表面活性剂囊泡克服乳腺癌中Akt诱导的治疗抗性
Mol Pharm. 2015 Dec 7;12(12):4214-25. doi: 10.1021/acs.molpharmaceut.5b00692. Epub 2015 Nov 10.
8
Toxicity of Nanoparticles and an Overview of Current Experimental Models.纳米颗粒的毒性及当前实验模型概述
Iran Biomed J. 2016;20(1):1-11. doi: 10.7508/ibj.2016.01.001. Epub 2015 Aug 19.
9
Knocking down disease: a progress report on siRNA therapeutics.攻克疾病：小干扰RNA疗法进展报告
Nat Rev Genet. 2015 Sep;16(9):543-52. doi: 10.1038/nrg3978.
10
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.使用纳米载体共递送小干扰RNA和治疗剂以克服癌症耐药性。
Nano Today. 2012 Aug 1;7(4):367-379. doi: 10.1016/j.nantod.2012.06.013.
Zotero 插件